Updates in psoriasis diagnosis and treatment status in China:results from the National Psoriasis Center Registry  

作　　者：Zhihui Yang Xinyu Yao Mingyue Wang Hang Li Ruoyu Li 

机构地区：[1]Department of Dermatology and Venereology,Peking University First Hospital,Beijing 100034,China [2]Beijing Key Laboratory of Molecular Diagnosis of Dermatoses,Peking University First Hospital,Beijing 100034,China [3]National Clinical Research Center for Skin and Immune Diseases,Beijing 100034,China [4]NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics,Peking University First Hospital,Beijing 100034,China

出　　处：《Chinese Medical Journal》2023年第23期2874-2876,共3页中华医学杂志（英文版）

基　　金：National Key Research&Development Program of China(No.2021YFF1201100)

摘　　要：To the Editor:Psoriasis is a common chronic immunemediated systemic inflammatory disease[1]characterized by irritating skin erythema,reduced quality of life,and associated systemic diseases including cardiovascular disease,diabetes,and metabolic syndrome.In 2017,0.5%of China’s population was diagnosed with psoriasis.[2]To improve the overall diagnosis and treatment level of psoriasis in China,the National Clinical Research Center for Skin and Immune Disease launched a national collaborative project called the Psoriasis Standardized Diagnosis and Treatment Center(also named Psoriasis Center)project,[3]in which the first national real-world big data collection platform,Psoriasis Center Registry,was established with more than 300 medical centers across China by 2022.This study aimed to update the current general characteristics and treatment distribution of patients with psoriasis in China by describing the registry data at enrollment.

关 键 词：diagnosis treatment REGISTRY 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]